Devgen receives IWT grant to support its obesity drug discovery program
27-Feb-2007
In its obesity program, Devgen takes a multidisciplinary approach to validate a novel class of kinase targets. According to the company, IWT's support for this program is very important for Devgen, not only from a funding perspective, but it is an endorsement of the innovative approach and validation opportunities of this program. The funding covers a period of 16 months.
Most read news
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Last viewed contents
Functional Genetics, Inc. - Gaithersburg, USA
Go to page
UGR Scientists design Molecules with a higher selective ability to exterminate cancer cells
Go to page
GeneProt and Lundbeck Collaborate in CNS Proteomics
Go to page
Enigma Diagnostics Expands Its US and European Executive Management Teams
Go to page
Clavis Pharma recruits first patient in pivotal Phase III study of elacytarabine in late-stage acute myeloid leukaemia - Clinical trial aims to confirm significant survival benefit seen in Phase II
Go to page
Researchers Create New Organic Gel Nanomaterials
Go to page
Wirtschaftsgenossenschaft deutscher Tierärzte eG - Garbsen, Germany
Go to page
Heart_block
Go to page
Reserpine
Go to page
Supergen and Astex Therapeutics enter definitive merger agreement
Go to page
Würschum GmbH - Ostfildern, Germany
Go to page